The company reported a loss on foreign currency exchange and net interest expense. Cash and cash equivalents decreased from the beginning to the end of the first quarter. The company was recently granted FDA approval for the investigational device exemption supplement for additional clinical trials for its dermaPACE.
More Articles on Orthopedic Devices:
14 Spine Devices Receive FDA 510(k) Clearance in April
MiMex Group Q1 Net Sales at $37M
US Spinal Implant Market to Reach $7B by 2018, Driven by Motion Preservation
SANUWAVE Reports $1.8M Q1 Net Loss
SANUWAVE reported revenues of $238,540 and net loss of $1.8 million during the first quarter of 2012.
Inside OHSU’s approach to data-driven perioperative staffing
Recommended Live Webinar on Mar 18, 2026 1:00 PM - 2:00 PM CST